1 Most
die within 1 h of transverse aortic constriction, probab
2 donation after cardiac death donors who will
die within 1 or 2 hrs after life-sustaining treatment ha
3 Most patients
die within 1 to 2 years of diagnosis.
4 emergency department for atrial fibrillation
die within 1 year of the visit.
5 bled before angiography were more likely to
die within 1 year than patients who did not bleed (8.5%
6 succumb to the disease and approximately 30%
die within 1 year, often sooner than those that have unr
7 One in five ICU survivors
die within 1 year, with advanced age and comorbidity bei
8 onventional chemotherapy, patients typically
die within 1 year.
9 ctions, organ dysfunction, and at least half
die within 1 year.
10 mutants exhibited cardiovascular defects and
died within 1 month.
11 Of these, 75 (5.3%)
died within 1 y during 1318 child-years of observation.
12 patients in a tertiary referral hospital who
died within 1 year after surgery and classified as surge
13 ly 1/3 of Tet2(-/-) and 8% of Tet2(+/-) mice
died within 1 year of age because of the development of
14 A total of 38 302 (19.4%)
died within 1 year of discharge, including 7.3% of patie
15 Of 18 102 patients discharged, 3461 (20%)
died within 1 year.
16 plete for 15 361 (99.7%), of whom 1758 (11%)
died within 1 year.
17 d mice transplanted with Dnmt3a-deleted HSCs
died within 1 year.
18 ansplants with 1-year follow-up, 576 (10.1%)
died within 1 year.
19 g some subjects who had required amputation)
died within 1 year.
20 mately 1 of 3 patients hospitalized with CAP
dying within 1 year.
21 th, of whom 1691 (27%) would be predicted to
die within 10 years from their disease.
22 pared with the other E. coli strains but all
died within 10 min on copper surfaces using a 'dry' inoc
23 injury, one in 137 girls and one in 64 boys
died within 10 y, and 54.2% of girls and 40.5% of boys h
24 ximately 1 in 20 mothers of infants with NAS
died within 10 years of delivery in both England and Can
25 re than one-third of patients with type 2 MI
dying within 10 years.
26 Thirty patients (16%)
died within 100 days of transplantation; only low serum
27 either untreated or treated with blank wafer
died within 11 days while the median survival for rats t
28 oncomitant pulmonary tuberculosis, and 14.7%
died within 12 months of EPTB diagnosis.
29 Sixty-four case patients who
died within 12 months of treatment-mediated viral suppre
30 Europe, and 255 in Latin America), 264 (19%)
died within 12 months.
31 ved to hospital discharge of which 76 (8.2%)
died within 12 months.
32 The incidence of AL was 6.4%, 744 patients
died within 120 days.
33 is, 76% of them died within 60 mins, and 83%
died within 120 mins after withdrawal of life-sustaining
34 rvival time was 8 years; however, 5 patients
died within 13 months of initiation of treatment.
35 x 10(4) cell/g, 60% of control C57BL/6 mice
died within 14 d compared with 100% mortality of alpha(X
36 A total of 18 (22%) patients
died within 14 days, including 12 (32%) in the CP-CRE gr
37 Only 13 (4%) patients
died within 14 days, primarily of refractory multiple or
38 tibiotic treatment administered, the odds of
dying within 14 days were more than 4 times greater for
39 Four infants
died within 15 days of follow-up in each group.
40 -19 infection, of whom 37% (95% CI, 23%-50%)
died within 15 days.
41 specificity of 60% to identify patients who
died within 16 months after ECP initiation.
42 Of the 389 enrolled patients, 133 (34.2%)
died within 180 days of ICU admission.
43 fidence interval 1.09-1.72, p</=.01) and for
dying within 180 days was 0.57 (confidence interval 0.44
44 he number of medically suitable patients who
die within 2 hours of planned withdrawal of life-sustain
45 were recovered because the patients did not
die within 2 hours.
46 iF2KO mice lose weight and
die within 2 weeks after the first tamoxifen dose.
47 ially dismal prognosis; >70% of GBM patients
die within 2 years of diagnosis.
48 t people have recurrence within 6 months and
die within 2 years.
49 ective therapies, two-thirds of IPF patients
die within 2-5 years from this progressive interstitial
50 y of heart defects while Nkx2-5(+/-) embryos
died within 2 days of hypoxic exposure.
51 A higher proportion of patients
died within 2 days of transplantation in LIST group (11%
52 periments showed that 73% of E. coli O157:H7
died within 2 h with a disinfection rate constant of k =
53 n = 1876) who died (n = 446; 24%), 272 (61%)
died within 2 years after listing.
54 ssessed for early progression (progressed or
died within 2 years after registration), progression-fre
55 D/G12D mice treated with MEK inhibitor alone
died within 20 weeks, and the remaining animals continue
56 lly normal at birth but declined rapidly and
died within 21 days.
57 itecture of the neocortex and cerebellum and
die within 24 h of birth.
58 ice display anuria and kidney hemorrhage and
die within 24 hours after birth.
59 ith amyloid transthyretin (ATTR) amyloidosis
die within 24 months of diagnosis.
60 us and S. pneumoniae, whereas untreated mice
die within 24-33 h.
61 One patient in the MSC group
died within 24 h of MSC infusion, but death was judged t
62 tients died and one-third 8 (34.8%) of these
died within 24 h.
63 ate address, or inadequate CT imaging or who
died within 24 hours of admission were excluded.
64 %) were severely injured (ISS > 15), and 80%
died within 24 hours of admission.
65 In contrast, Six2 (Cre) Dnmt1 (f/f) mice
died within 24 hours of birth, from a severe kidney deve
66 ients (5%) and 85 of 447 nonrecipients (19%)
died within 24 hours of MEDEVAC rescue (between-group di
67 d that both models developed arrhythmias and
died within 24 hours, while wild-type mice were free of
68 patients who unsuccessfully donated (67.5%)
died within 24 hours.
69 % were in shock; 28% were transfused; and 6%
died within 24 hours.
70 long-term whereas all control group animals
died within 24 hours.
71 resent a dramatic phenotype with 60% of pups
dying within 24 h of birth and the surviving animals exh
72 GATA4 and GATA6 in the intestinal epithelium
died within 24h of birth.
73 Among them, 26 (37%)
died within 28 days after ICU admission and were classif
74 110 patients (25.7%) in the usual care group
died within 28 days after randomization (age-adjusted ra
75 patients from all three cohorts, of whom 359
died within 28 days of admission to the intensive-care u
76 4 days of ICU admission, 350 of whom (54.9%)
died within 28 days of ICU admission.
77 copies/microl plasma) had increased odds of
dying within 28 d of ICU admission in both the BWH RoCI
78 -knock-out (KO) mice are born alive but most
die within 3 d after birth showing no overt defects in a
79 8(-/-)) mice that lack core fucose structure
die within 3 days after birth, but the remainder survive
80 egenerating, lose their active behaviors and
die within 3 months.
81 The latter 2 subjects
died within 3 and 11 days of enrollment whereas the 36-y
82 PEB2 knock-out (KO) mice and found that most
died within 3 d after birth.
83 Patients who
died within 3 days of admission were excluded from analy
84 Patients who
died within 3 days of peak troponin concentration withou
85 Of the 1976 patients with NSTEMI, 101
died within 3 days of their peak troponin concentration
86 evertheless, 10 of 42 split liver recipients
died within 3 months after transplantation.
87 Two enrolled patients
died within 3 months of treatment from pre-existing como
88 erapy, 68% of meningitis patients (23 of 34)
died within 3 months.
89 susceptible to SFTSV infection, and all mice
died within 3 to 4 days after subcutaneous inoculation o
90 The occasional survivors had stunted growth,
died within 3 wk, and showed abnormalities of striatal d
91 ng persons with HCV who died, more than half
died within 3 years of an HCV report to DOHMH.
92 Nearly one-third of Medicare ICD recipients
died within 3 years, reflecting a population with more a
93 Patients
dying within 3 months had significantly higher hepcidin
94 Interestingly, patients
dying within 3 months on the waiting list displayed elev
95 IL-2-KO) mice develop systemic autoimmunity,
dying within 3 to 5 wk from complications of autoimmune
96 pitalized, visit an emergency department, or
die within 30 days after discharge from an acute hospita
97 nostic value to discriminate those likely to
die within 30 days for the model with peak TnT measureme
98 IS volumes <126 annually are more likely to
die within 30 days than patients admitted to hospitals t
99 surgery each year, more than 1 million will
die within 30 days.
100 who required mechanical ventilation) and 12%
died within 30 d.
101 (15%), 43 died in the hospital (7%), and 72
died within 30 days (12%).
102 re readmitted or died within 30 days; 72,472
died within 30 days (4.7%; 99% CI, 4.7%-4.8%), and 321,7
103 nts admitted as weekend emergency admissions
died within 30 days (p<0.0001).
104 Twenty-seven (32%) patients
died within 30 days after a MBE.
105 Only 0.7% of patients
died within 30 days after admission (50 deaths), and mos
106 There were 5502 patients (26.7%) who
died within 30 days after admission.
107 Patients who
died within 30 days after TAVI were excluded.
108 A total of 19 patients (3.4%)
died within 30 days after the MitraClip procedure.
109 5 patients were included, of whom 539 (0.6%)
died within 30 days and 1264 (1.4%) required ICU admissi
110 placement, and 15.8% needed ventilation; 23%
died within 30 days and 21.6% developed second infection
111 14 (13%) of 105 patients
died within 30 days and 27 (26%) died within 60 days.
112 Two patients in the EPP group
died within 30 days and a further patient died without l
113 could successfully discriminate patients who
died within 30 days and those who did not.
114 Two patients (4.3%)
died within 30 days due to sepsis and gastroduodenal art
115 Forty-nine patients (23.6%) who
died within 30 days had higher admission MELD (25 versus
116 All patients who
died within 30 days of a PCI from January 2009 to April
117 s were substantially longer in patients that
died within 30 days of admission.
118 One patient
died within 30 days of CHLT.
119 in the emergency department, and 840 (7.5%)
died within 30 days of discharge.
120 patients and none of the 29 control patients
died within 30 days of enrollment (P=.58).
121 e negative (p = 0.0023) as well as those who
died within 30 days of hospital admission (p = 0.025).
122 Higher percentages of patients with AKI
died within 30 days of hospitalization (34% vs 7%), were
123 g PCI during the study period, 1674 patients
died within 30 days of PCI (1.5%).
124 The cause of death among patients who
died within 30 days of PCI in a national healthcare syst
125 s and Results We identified all patients who
died within 30 days of PCI in the Veterans Affairs (VA)
126 over a median 110 days, of whom 995 (17.2%)
died within 30 days of radiotherapy commencement.
127 Six patients (8%)
died within 30 days of registration.
128 ed for influenza across the 6 seasons, 6,837
died within 30 days of specimen collection.
129 treated with induction therapy and those who
died within 30 days of surgery were excluded from analys
130 Six patients (3.9%)
died within 30 days of surgery, and overall 1-year morta
131 lications (18.3%), and 18924 patients (2.7%)
died within 30 days of surgery.
132 ncluded 14,037 patients, 267 (1.9%) patients
died within 30 days of surgery.
133 patients (24.53%), and 114 patients (4.27%)
died within 30 days of surgery.
134 nfidence interval 7.5-16.2%); seven children
died within 30 days of their episode of convulsive statu
135 1013 (33.3%) received statins and 151 (5.0%)
died within 30 days of their influenza test.
136 27 patients
died within 30 days of treatment in the cabazitaxel and
137 In the ACEI/ARB group, 18.1%
died within 30 days vs 7.3% in the nonuser group, but th
138 from 59 patients who presented with ACS and
died within 30 days were included.
139 5% CI 0.74-0.85; P = .002), and patients who
died within 30 days with an AUC of 0.77 (95% CI 0.73-0.8
140 9 of 73 (26%) patients in the overall cohort
died within 30 days, but there was no significant differ
141 or epinephrine, suffered cardiac arrest, or
died within 30 days.
142 e, 59 years) were included; 39 (6%) patients
died within 30 days.
143 te peripheral blood count recovery), and 18%
died within 30 days.
144 Of these, 102 (8.2%)
died within 30 days.
145 .3%; 99% CI, 23.3%-23.5%) were readmitted or
died within 30 days; 72,472 died within 30 days (4.7%; 9
146 We identified 316 patients, of whom 46%
died within 30-days.
147 (all P < 0.04), and were at greater odds of
dying within 30 days after colectomy, heart valve repair
148 ent increased the likelihood of an inpatient
dying within 30 days of admission by 7% (odds ratio 1.06
149 ctors on the likelihood of surgical patients
dying within 30 days of admission, before and after adju
150 039-1.294) increase in the odds of a patient
dying within 30days of admission respectively.
151 epithelial cells develop immunotoxicity and
die within 32 days, indicating that GI tract inducible C
152 participants with M. tuberculosis bacteremia
died within 36 days of enrollment.
153 adult sensory ganglia, up to 27% of neurons
die within 4 days (d) in culture and this can be prevent
154 Among 708 patients, 86 (12%)
died within 4 days, 140 (20%) died between days 4 and 28
155 Two patients in the usual-care group
died within 4 weeks after randomization from causes cons
156 out mice that showed massive proteinuria and
died within 4 weeks of birth.
157 19 (39%) had resistant disease, and two (4%)
died within 4 weeks of starting treatment.
158 Whereas all GCase-inhibited mice
died within 4-5 weeks, mice deficient in both GCase and
159 Seven patients (58.3%)
died within 42 days of onset of bIFI.
160 ly 40% of Cx30/Cx47 double-deficient animals
died within 42 to 90 d after birth, accompanied by sever
161 tectable Nissl substance) at 12-24 hours and
die within 48 hours.
162 ith bicuspid aortic valves, and patients who
died within 48 h after AVR were excluded.
163 Two of the TKM-130803 recipients
died within 48 h of admission and were therefore exclude
164 y 14 after admission, excluding patients who
died within 48 h of admission.
165 erapies other than BL/D-C, had pneumonia, or
died within 48 hours of admission.
166 All irradiated mice
died within 5 d of infection, whereas no mortality was s
167 posed to the pathogen, and all of these mice
died within 5 days of infection.
168 ockade as monotherapy or combination therapy
died within 5 years of diagnosis.
169 d adenocarcinoma of the esophagus, 323 (53%)
died within 5 years of surgery, and 235 (39%) died of tu
170 36.1% underwent retransplantation and 15.4%
died within 5 years.
171 50.4% underwent retransplantation and 12.1%
died within 5 years; after the second graft failure, 36.
172 in endothelin-1 plasma levels, with all mice
dying within 5 wk.
173 ll those given control antibody or anti-PD-1
died within 50 days, whereas 43% of mice given anti-OX40
174 Cre(ERT2)/Myocd(F/F) conditional mutant mice
die within 6 mo of Myocd gene deletion, exhibiting profo
175 [CI], 1.5 to 3.6) and 3.7 times as likely to
die within 6 months after therapy (95% CI, 2.3 to 5.9).
176 olled in Medicare who are admitted to an ICU
die within 6 months of admission.
177 immunoglobulin light chain (AL) amyloidosis
die within 6 months of diagnosis and 25% of patients wit
178 nd older admitted to the intensive care unit
die within 6 months of hospital discharge.
179 or chemotherapy whom oncologists expected to
die within 6 months were interviewed before and after a
180 active turtles released with satellite tags
died within 6 days.
181 All recipients in WI-SCS group
died within 6 hours after transplantation.
182 the basis of clinical outcome: patients who
died within 6 mo (group 1 [G1], n = 4), survived 6-12 mo
183 patients with the highest liver tumor burden
died within 6 mo of treatment, with treatment considered
184 Patients who
died within 6 months after surgery were excluded.
185 Four (9%) patients
died within 6 months after surgery.
186 Fewer patients
died within 6 months of diagnosis in the 2 later periods
187 215 (10%) of all women had
died within 6 months of diagnosis, but 3-year overall su
188 However, most patients with HF who
died within 6 months of hospital discharge did not recei
189 ath before discharge (93%), 112 patients had
died within 6 months of medical ICU discharge, and only
190 eceived prolonged mechanical ventilation and
died within 6 months of their index procedure spent the
191 not receiving hospice referrals, 1608 (20%)
died within 6 months post discharge (the hospice-eligibl
192 on these 3 variables identified patients who
died within 6 months, with c-statistic values of 0.89 (9
193 n of 2.4 years, 415 patients died: 108 (26%)
died within 6 months.
194 or NY-ESO-1 and 23% for Melan-A in those who
died within 6 months.
195 kb1 mice exhibited body weight reduction and
died within 6 weeks after tamoxifen induction.
196 No patients
died within 6 weeks of induction.
197 requires identification of patients who will
die within 60 min of withdrawal of life-sustaining treat
198 The probability to
die within 60 mins for each patient in this validation s
199 imination (distinction of those patients who
die within 60 mins from those who do not, expressed by t
200 Half of all ICU patients
die within 60 minutes of withdrawal of cardiorespiratory
201 uded patients who experienced progression or
died within 60 days of activity assessment and used Cox
202 dmitted with upper gastrointestinal bleeding
died within 60 days of admission, signifying a high burd
203 t patients died on TKI therapy, two patients
died within 60 days of being off TKIs, and 23 patients d
204 Two patients, both immunocompromised adults,
died within 60 days of symptom onset.
205 of interest; 71,583 of these patients (8.2%)
died within 60 days of their index operation.
206 05 patients died within 30 days and 27 (26%)
died within 60 days.
207 Cases were children who
died within 60 days.
208 59 of 82 patients who
died within 60 min of WLST had DCD-N scores of 3 or more
209 We included 178 patients, 82 (46%) of whom
died within 60 min of WLST.
210 odel discriminated well between patients who
died within 60 mins after withdrawal of life support and
211 th donors, 211 entered analysis, 76% of them
died within 60 mins, and 83% died within 120 mins after
212 Fifty (61%)
died within 60 mins.
213 carcinoma and neuroendocrine tumors, and all
died within 65 weeks.
214 ndred ninety-six patients were readmitted or
died within 7 days of discharge.
215 hospice was 15, and 39% of the beneficiaries
died within 7 days of enrollment.
216 Eight patients
died within 7 days of the index request: five in the GP-
217 The percentage of patients with AMI who
died within 7 days, 30 days, 90 days, 9 months, and 1 ye
218 The animal
died within 7 minutes of VAE.
219 Approximately 15% of all patients had
died within 7 to 9 years of follow-up.
220 no mice achieved complete remission and all
died within 75 days.
221 Two neonates born live in the ETU
died within 8 days.
222 t differ after exclusion of participants who
died within 8 years of baseline.
223 Three
died within 8 years of primary HCV infection, and 1 surv
224 nimals, whereas RC/RC- and RW/RW-mutant mice
died within 9 days after birth.
225 ed to synthesize BZLF1 RNA, with 90% of them
dying within 9 days postinfection.
226 anterior circulation, 60 to 80% of patients
die within 90 days after stroke onset or do not regain f
227 tment, patients with ALD were less likely to
die within 90 days when compared with patients with NASH
228 d CDI within 30 days after the index test or
died within 90 days after the index toxin EIA date.
229 Of 10,159 patients listed for HT, 596 (5.9%)
died within 90 days and 1,054 (10.4%) within 1 year with
230 Of 2034 HT recipients, 6.8%
died within 90 days and 10.8% within 1 year.
231 Only 26% of candidates removed as "too sick"
died within 90 days of delisting; 6335 deaths after deli
232 ncer between 2000 and 2010, 209 patients who
died within 90 days of surgery and 296 patients with a R
233 1743 patients
died within 90 days of surgery during 8 years, with a su
234 In the standard TTS arm 5 patients (4.3%)
died within 90 days of surgery, compared to 4 patients (
235 rrence, we excluded patients who recurred or
died within 90 days of their multivitamin assessment.
236 ive complications on mortality, patients who
died within 90 days postoperative were excluded.
237 available for analysis of whom 3797 (30.4%)
died within 90 days.
238 statins before blood cultures and 677 (32%)
died within 90 days.
239 Forty-five neonates (33.1%) ultimately
died within 90 minutes of withdrawal of life-sustaining
240 tive TB blood culture, of these 9/41 (22.0%)
died within 90-days.
241 culture-positive patients, including 9/9 who
died within 90-days.
242 ienced a significant decrease in the odds of
dying within 90 days of admission compared with patients
243 However, they are small, and 60%
die within a few hours after birth.
244 Mice are born but never feed and
die within a few hours.
245 Animals usually
die within a few months with no evidence of antibody or
246 sive neurodegenerative process, and patients
die within a few years after disease onset.
247 ants have a growth retardation phenotype and
die within a month after birth.
248 patients with M. tuberculosis bacteremia may
die within a month of hospitalization.
249 ch as 70% of patients over 60 years old will
die within a year of diagnosis.
250 lt mice (cFlip(iDeltaIEC) mice), the animals
died within a few days from severe tissue destruction, e
251 ted patients developed cardiogenic shock and
died within a few days of T-cell infusion, events not pr
252 rolled tuberculosis patients, 9% of patients
died within a median follow-up period of 2.9 years: 342
253 omogram score, approximately 50% of patients
died within a year of resection.
254 in an adenosine kinase-dependent process and
dies within a few hours.
255 fraction is high, with one third of patients
dying within a year.
256 Most patients
died within an hour of left ventricular assist device de
257 The activity of the rather dilute enzyme
dies within approximately 60 min.
258 cardiac disease, and hyperoxia-treated mice
die within days from acute pulmonary edema.
259 Upon return to normoxia, Ndufs4 KO mice
die within days.
260 absorption was perturbed, and neonatal mice
died within days of birth.
261 Males were also more likely to
die within each age range assessed (eg, 15-24, 25-29, 30
262 water live for weeks, whereas the same cells
die within hours if transferred into water with 2% gluco
263 psis, and in established cases an infant may
die within hours of diagnosis.
264 tive barrier to the external environment and
died within hours of birth.
265 Without oxygen, most vertebrates
die within minutes as they cannot meet cellular energy d
266 urvival is highly variable, as some patients
die within months, while others live for many years.
267 oma patients with metastatic disease usually
die within one year, emphasizing an urgent need to devel
268 s of the RRT event and many patients (46.8%)
died within one day of the consultation.
269 rom the derivation cohort (n = 95 977), 2.7%
died within one year.
270 VOC profiles from children who
died within six days following admission were compared t
271 omyopathy undergo a heart transplantation or
die within the first 2 years after diagnosis.
272 Patients who
died within the 14 day study period were recorded as hav
273 When combined, only one of nine mice
died within the 30-week study; aortic histology and diam
274 a at their last visit, known APOE4 genotype,
died within the ensuing 24 months, and underwent neuropa
275 ,640 people who started treatment, 58 (1.6%)
died within the first 16 weeks in care, and an additiona
276 action less than 40%, and excluded those who
died within the first 3 months.
277 Four patients (2 in each group)
died within the first 30 postoperative days.
278 at 365 days even after removing patients who
died within the first 30 postoperative days.
279 Three subjects (2%)
died within the first 7 days, 107 (79%) exhibited rapid
280 We excluded patients who
died within the first 72 hr after transplantation, were
281 Half of patients (n = 22; 8.6%)
died within the first five years.
282 Of the 71 617 patients, 7878 (11%) had
died within the first month; of these, stroke was the ca
283 While some mutant mice
died within the first week after birth, others survived
284 Eighty-one patients
died within the first year after HDM/SCT and were not ev
285 ult of respiratory failure, and five of them
died within the first year of life.
286 Sixty of 346 patients (17%)
died within the first year.
287 lthough a substantial proportion of patients
died within the first year.
288 0%) with troponin concentrations >0.01 ng/mL
died within the follow-up period, 7 of which had concent
289 bal autopsy, which was done on all those who
died within the study areas.
290 1980s, 18% of those who survived for 5 years
died within the subsequent 25 years.
291 a, potentially salvageable brain tissue that
dies within the first few hours after blood flow cessati
292 conditional knockout mice failed to survive,
dying within the first 24 hours of birth.
293 The risk of
dying within the first three years after a HL diagnosis
294 rriers to access to surgical care of persons
dying within the past year were analyzed.
295 sitivity), and 75 of 96 of those who did not
die within this interval had scores of 0-2 (78% specific
296 Four of the control animals
died within this period (p=0.03).
297 It was highest for upper GI malignancy (95%
died within three years) and varices (52%).
298 Although the majority of these cells
die within two weeks of their birth, they can be rescued
299 erapies, however, 20% of patients relapse or
die within two years and are deemed high risk.
300 tching to a high fat diet, the mice begin to
die within weeks and display signs of severe hypertrophi